Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by EFG Asset Management Americas Corp.

Key Points

• EFG Asset Management Americas Corp. reduced its stake in Alnylam Pharmaceuticals by 10.5%, now holding 13,372 shares valued at approximately $3.61 million.
• Alnylam Pharmaceuticals reported a missed earnings per share estimate of ($0.51), compared to the consensus estimate of ($0.05), reflecting a negative net margin of 11.49%.
• Many analysts maintain a positive outlook on Alnylam, with ratings indicating a "Moderate Buy" and an average target price of $350.75.

EFG Asset Management Americas Corp. decreased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 10.5% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 13,372 shares of the biopharmaceutical company's stock after selling 1,574 shares during the quarter. EFG Asset Management Americas Corp.'s holdings in Alnylam Pharmaceuticals were worth $3,611,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of ALNY. Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares during the period. Crossmark Global Holdings Inc. bought a new position in Alnylam Pharmaceuticals in the 1st quarter worth about $275,000. GAMMA Investing LLC increased its position in shares of Alnylam Pharmaceuticals by 14.3% during the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock worth $166,000 after acquiring an additional 77 shares during the period. Brighton Jones LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $243,000. Finally, Silvercrest Asset Management Group LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $1,151,000. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock traded up $9.56 during trading hours on Friday, hitting $401.80. The company's stock had a trading volume of 1,780,984 shares, compared to its average volume of 1,028,799. The stock has a market cap of $52.39 billion, a PE ratio of -162.67 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $402.43. The company has a 50 day moving average of $318.24 and a 200 day moving average of $278.80. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 444.38% and a negative net margin of 12.96%. Alnylam Pharmaceuticals's revenue for the quarter was up 20.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.16) earnings per share. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the sale, the chief executive officer owned 48,948 shares in the company, valued at approximately $14,978,088. This represents a 28.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Needham & Company LLC upped their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a report on Thursday. Barclays increased their price objective on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a research note on Friday. Scotiabank boosted their price objective on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a research note on Friday. JPMorgan Chase & Co. increased their target price on Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the company an "overweight" rating in a research report on Wednesday, July 16th. Finally, Jefferies Financial Group lifted their price target on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a report on Monday, July 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-three have assigned a buy rating to the company's stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $392.13.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.